Valproic acid induced Stevens–Johnson syndrome
- Authors: Somov D.V.1, Chernyaeva A.Y.1, Mazus V.A.2, Nurieva L.T.2, Bobrov M.A.3, Anichkov D.A.1
- 
							Affiliations: 
							- Pirogov Russian National Research Medical University
- N.I. Pirogov City Clinical Hospital No. 1
- Moscow Scientific and Practical Center of Dermatology and Venerology and Cosmetology of the Department of Health
 
- Issue: Vol 100, No 3 (2024)
- Pages: 74-79
- Section: CLINICAL CASE REPORTS
- URL: https://journals.rcsi.science/0042-4609/article/view/262340
- DOI: https://doi.org/10.25208/vdv10515
- ID: 262340
Cite item
Full Text
Abstract
A 27-year-old transgender female at the stage of gender transition with bipolar disorder for which she received valproic acid developed multiple petechial rashes on the chest, upper and lower extremities, local erythematous lesions with forming blisters, large-platelet peeling on the face, neck, chest and inguinal area, erosion on the oral mucosa. She was diagnosed with drug eruption, Stevens–Johnson syndrome. The diagnosis was verified on the basis of complaints, medical history, clinical picture, laboratory findings. Treatment included valproic acid withdrawal, dexamethasone, infusion therapy, vancomycin, cyclosporine A. Against the background of the therapy, skin condition was improved: there was the epithelization of ulcerative defects and the absence of new elements.
Full Text
##article.viewOnOriginalSite##About the authors
Dmitry V. Somov
Pirogov Russian National Research Medical University
							Author for correspondence.
							Email: somovmd@yandex.ru
				                	ORCID iD: 0000-0002-8874-3663
				                	SPIN-code: 5096-6710
																		                								
Assistant Lecturer
Russian Federation, MoscowAlina Yu. Chernyaeva
Pirogov Russian National Research Medical University
														Email: alinaache23@gmail.com
				                	ORCID iD: 0000-0002-7142-2484
				                																			                												                	Russian Federation, 							Moscow						
Veronika A. Mazus
N.I. Pirogov City Clinical Hospital No. 1
														Email: veroni2001@list.ru
				                	ORCID iD: 0000-0002-3754-5333
				                																			                												                	Russian Federation, 							Moscow						
Lyaman T. Nurieva
N.I. Pirogov City Clinical Hospital No. 1
														Email: lemi_enigma@mail.ru
				                	ORCID iD: 0000-0002-6312-0291
				                																			                												                	Russian Federation, 							Moscow						
Maxim A. Bobrov
Moscow Scientific and Practical Center of Dermatology and Venerology and Cosmetology of the Department of Health
														Email: m.a.bobrov@yandex.ru
				                	ORCID iD: 0000-0001-7374-0374
				                	SPIN-code: 3058-6092
																		                												                	Russian Federation, 							Moscow						
Dmitry A. Anichkov
Pirogov Russian National Research Medical University
														Email: d.anichkov@gmail.com
				                	ORCID iD: 0000-0001-5610-4819
				                	SPIN-code: 2891-6763
																		                								
MD, Cand. Sci. (Med.), Assistant Professor
Russian Federation, MoscowReferences
- Кубанов А.А., Горланов И.А., Самцов А.В., Хайрутдинов В.Р. Синдром Стивенса–Джонсона. Клинические рекомендации Российского общества дерматовенерологов и косметологов. М.; 2020. [Kubanov AA, Gorlanov IA, Samcov AV, Khairutdinov VR. Stevens-Johnson syndrome. Clinical guidelines of Russian society of dermatovenereologists and cosmetologists. Moscow; 2020. (In Russ.)]
- Дюбкова Т.П., Жерносек В.Ф. Интенсивная терапия синдрома Стивенса–Джонсона — токсического эпидермального некролиза у детей. Экстренная медицина. 2013;3(7):92–108. [Dyubkova TP, Zhernosek VF. Intensive care of Stevens–Jonson syndrome — toxic epidermal necrolysis in children. Emergency medicine. 2013;3(7):92–108. (In Russ.)]
- McNamara JO. Pharmacotherapy of the epilepsies. Brunton LL, Lazo JS, Parker KL, Goodman & Gilman’s the pharmacological basis of therapeutics. 11th ed. N.Y.: McGraw Hill; 2006. P. 521–548.
- Rashid M, Kashyap A, Undela K. Valproic acid and Stevens-Johnson syndrome: a systematic review of descriptive studies. Int J Dermatol. 2019;58(9):1014–1022. doi: 10.1111/ijd.14411
- Kumar PN, Kumar SK. Stevens–Johnson syndrome induced by sodium valproate. Indian J Psychiatry. 2004;46(3):269–270.
- Baba M, Karakas M, Aksungur VL, Homan S, Yücel A, Acar MA, et al. The anticonvulsant hypersensitivity syndrome. J Eur Acad Dermatol Venereol. 2003;17:399–401. doi: 10.1046/j.1468-3083.2003.00750.x
- Charlton AA, Harris W, Fan K, Mouton E, Jackson S, Cooper A. Toxic epidermal necrolysis and Stephen-Johnson syndrome: a comprehensive review. Adv Wound Care (New Rochelle). 2020;9(7):426–439. doi: 10.1089/wound.2019.0977
- Hu CH, Chang NJ, Liu EW, Chuang SS, Chung WH, Yang JY. SCORTEN and impaired renal function related to mortality of toxic epidermal necrolysis syndrome patients in the Asian population. J Eur Acad Dermatol Venereol. 2013;27(5):628–633. doi: 10.1111/j.1468-3083.2012.04502.x
- Torres-Navarro I, Briz-Redon A, Botella-Estrada R. Accuracy of SCORTEN to predict the prognosis of Stevens-Johnson syn-drome/Toxic Epidermal Necrolysis: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2020;34(9):2066–2077. doi: 10.1111/jdv.16137
- Imahara SD, Holmes JH, Heimbach DM, Engrav LE, Honari S, Klein MB, et al. SCORTEN Overestimates Mortality in the Setting of a Standardized Treatment Protocol. J Burn Care Res. 2006;27(3):270–275. doi: 10.1097/01.BCR.0000216532.71360.9B
Supplementary files
 
				
			 
					 
						 
						 
				





